298 related articles for article (PubMed ID: 34680298)
1. New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.
Villa M; Sharma GG; Manfroni C; Cortinovis D; Mologni L
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680298
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.
Manicone M; Scaini MC; Rodriquenz MG; Facchinetti A; Tartarone A; Aieta M; Zamarchi R; Rossi E
J Thorac Dis; 2017 Oct; 9(Suppl 13):S1391-S1396. PubMed ID: 29184678
[TBL] [Abstract][Full Text] [Related]
3. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
4. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
[TBL] [Abstract][Full Text] [Related]
5. The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells.
Kulasinghe A; Lim Y; Kapeleris J; Warkiani M; O'Byrne K; Punyadeera C
Cells; 2020 Jun; 9(6):. PubMed ID: 32549278
[TBL] [Abstract][Full Text] [Related]
6. Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients.
Provencio M; Pérez-Callejo D; Torrente M; Martin P; Calvo V; Gutiérrez L; Franco F; Coronado MJ; Cruz-Bermúdez JL; Ruiz-Valdepeñas AM; Cruz-Bermúdez A; Sánchez-Beato M; Romero A; García-Grande A
Oncotarget; 2017 Aug; 8(35):59408-59416. PubMed ID: 28938646
[TBL] [Abstract][Full Text] [Related]
7. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
[TBL] [Abstract][Full Text] [Related]
8. The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.
Chen Y; Guo W; Fan J; Chen Y; Zhang X; Chen X; Luo P
Cancer Manag Res; 2017; 9():801-811. PubMed ID: 29263703
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing to dynamically detect mechanisms of resistance to
Sánchez-Herrero E; Blanco Clemente M; Calvo V; Provencio M; Romero A
Transl Lung Cancer Res; 2020 Apr; 9(2):366-372. PubMed ID: 32420077
[TBL] [Abstract][Full Text] [Related]
11. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
14. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.
Carnesecchi S; Rougemont AL; Doroshow JH; Nagy M; Mouche S; Gumy-Pause F; Szanto I
Free Radic Biol Med; 2015 Jul; 84():22-29. PubMed ID: 25797883
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of
Agarwal I; Sabatini L; Alikhan MB
Front Oncol; 2020; 10():730. PubMed ID: 32457846
[No Abstract] [Full Text] [Related]
16. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
17. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic strategies in advanced ALK positive non-small cell lung cancer].
Tiotiu A; Billon Y; Vaillant P; Menard O; Hofman P; Mascaux C
Rev Mal Respir; 2019 Dec; 36(10):1107-1116. PubMed ID: 31727555
[TBL] [Abstract][Full Text] [Related]
19. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
Wang X; Wu J; Zhang M
Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
